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Abstract
The purpose of the present study was to examine the relation of total antioxidant status (TAS) to metabolic risk factors in Korean adults. Anthropometric
measures, blood pressure, serum lipids and fasting glucose were determined in 406 men and women. TAS was measured by using commercially
available Randox kit. Serum TAS was significantly positively correlated with body weight (p=0.004), body mass index (BMI) (p=0.033), waist
circumference (p=0.017), total cholesterol (p=0.038) and triglyceride (TG) (p<0.001). The mean TAS of hypertriglyceridemic subjects (TG ≥150
mg/dl) was significantly higher than that of subjects whose TG was lower than 150 mg/dl (p=0.001). When central obesity, TG, high density lipoprotein
cholesterol, fasting glucose and blood pressure were considered as metabolic risk factors, TAS was shown to be elevated with increased number 
of metabolic risk factors (p=0.004). The positive association between TAS and a number of metabolic risk factors suggests that increased TAS
may not always indicate one’s healthier condition. In order to help understand TAS as a marker of total antioxidant capacity in humans with various
metabolic conditions, it is needed to clarify the factors affecting TAS in relation to changes in metabolic risk factors.
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Introduction14)
Total antioxidant capacity (TAC) assays have been designed 
to determine overall antioxidant power of samples contributed 
by antioxidant and their interactions. Evaluation of TAC in body 
fluid has been used as one of the biological markers for 
monitoring oxidative stress in humans (Kim et al., 2000; Kim 
et al., 2001; Mendoza-Nunez et al., 2001). In order to assess 
TAC, several methods have been developed and used for the 
last 20 years. The oxygen radical absorbance capacity (ORAC) 
(Cao et al., 1993), the ferric reducing ability of plasma (FRAP) 
(Benzie & Strain, 1996) and the trolox equivalent antioxidant 
capacity (TEAC)(Miller et al., 1993) are well known methods. 
The TEAC assay is based on the inhibition of the absorbance 
of ABTS (2,2'-Azino-di-[3-ethylbenzthiazoline sulphonate]) radi-
cal cation by antioxidants in the tested sample.  In addition, the 
TEAC assay of Miller et al. (1993) has been commercialized 
as “Total Antioxidant Status (TAS)” kit by Randox Laboratories 
and introduced its automated way of assay. 
While the pathological increase of free radical generation has 
been well recognized in various disease states, the commercially 
available TAS kit has been widely used to determine in vivo 
free radical trapping power in patients with various disease 
conditions. In relation with several diseases, plasma or serum 
TAS was consistently decreased in patients with cancer (Jeon 
et al., 1998), hypertension (Kim et al., 2006), osteoporosis 
(Altindag  et al., 2007) and psoriasis (Kural et al., 2003), but 
was not significantly changed in patients with acute myocardial 
infarction (Markovic et al., 2000).  Besides disease conditions, 
TAS assay also has been employed as a marker in determining 
age-related oxidative stress in healthy humans and exercise 
induced oxidative stress in athletes. TAS has shown to be 
decreased in older people (Mendoza-Nunez et al., 2007), but 
increased in athletes right after exercise (Kim et al., 2001; 
Magalhaes et al., 2007). These findings suggested that oxidative 
stress inducing conditions might not always results in reduction 
of TAS in circulation. Previous studies on antioxidant capacity 
in people with overweight and obesity have failed to show 
decreased TAS level (Bae, 2006; Kim et al., 2000; Molnar et 
al., 2004), although increased oxidative stress with obesity has 
been well presented (Mohn et al., 2007). 
In previous studies, no consensus was made in the relationship 
between serum or plasma TAS and oxidative stress, since serum 
or plasma TAS has not consistently reflect the conditions which 
are considered to have increased oxidative stress. In addition, 
there are relatively large number of studies looking at changes 
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Table 1. Anthropometric and biochemical indicators of subjects
Mean ± SD
Total
(n=406)
Males
(n=74)
Females
(n=332)
Age (yrs)  47.90±10.57  46.66±10.75  48.17±10.53
Height (cm) 162.22±7.05 172.47±4.77 159.94±5.20
**
Weight (kg)  59.14±10.16  72.95±7.88  56.06±7.77
**
BMI (kg/m
2)  22.39±3.02  24.51±2.34  21.92±2.96
**
Waist circumference (cm)  79.24±10.09  88.52±7.34  77.25±9.48
**
Waist-Hip ratio   0.85±0.08   0.91±0.05   0.84±0.084
**
Systolic blood pressure 
(mmHg) 113.01±14.77 121.66±14.41 111.07±14.17
**
Diastolic blood pressure 
(mmHg)  73.19±10.73  80.01±9.66  71.66±10.36
**
Total cholesterol (mg/dl) 195.43±35.40 198.43±38.360 194.77±34.74
TG (mg/dl) 118.87±91.13 183.19±129.21 104.54±73.13
**
LDL-cholesterol (mg/dl) 112.20±31.79 111.87±38.80 112.27±30.08
HDL-cholesterol (mg/dl)  59.57±13.28  50.09±9.70  61.69±13.06
**
Glucose (mg/dl)  90.72±25.65  94.30±17.88  89.92±27.04
TAS (mmol/L)   0.97±0.34   1.09±0.34   0.95±0.33
*
*p＜0.01,  **p＜0.001,  significantly  different  from  males  by  independent  samples 
t-test
in TAS with certain metabolic conditions such as diseases, 
exercise, obesity and diet alteration with antioxidant supplemen-
tation (Rasool et al., 2006; Tsakiris et al., 2007). However, there 
is still lack of studies to assess TAS for large numbers of people 
in various metabolic conditions and to examine how TAS are 
related with individual metabolic risk factors associated with 
various metabolic conditions. Therefore, the purpose of the 
present study was to examine the relationship between serum 
TAS and metabolic risk factors such as obesity, high blood 
pressure, high serum lipid and glucose. It is expected that the 
findings from the current study can be utilized as basic data to 
evaluate total antioxidant capacity of Korean adults using the 
commercially available TAS assay. 
Subjects and Methods 
Study participants included 406 Korean adult men and women 
living in the Seoul area. A single blood sample from each subject 
was collected in vacutainer tubes after an overnight fast. Serum 
samples were separated from whole blood for analyzing lipid, 
glucose, total antioxidant status and the sample aliquots were 
stored at -80℃ until analyses. Subjects' weight, height, and waist 
and hip circumferences were measured by trained technicians. 
The BMI was calculated as weight (kg) divided by height (m
2). 
Waist circumference to hip circumference ratio (WHR) was 
calculated as the ratio between waist and hip circumferences. 
Trained technicians were assigned to measure blood pressure with 
a semiautomatic device, with subjects in the sitting position after 
at least 2 min of rest. 
Serum total cholesterol (TC), low-density lipoprotein (LDL) 
cholesterol, high density lipoprotein (HDL) cholesterol, trigl-
yceride (TG) and fasting glucose concentrations were measured 
by ADVIA
® 1650 chemistry system (Bayer HealthCare LLC, 
Germany). Total antioxidant status (TAS) in serum was measured 
by total antioxidant quantification using ABTS
+  (2,2'-Azino-di- 
[3-ethylbenzthiazoline sulphonate]) radical formation with the 
commercially available Randox Total Antioxidant Status test kit 
(Randox Lab., Ltd., UK). Assay was performed using the Victor 
multilabel microplate reader (PerkinElmer Life and Analytical 
Sciences, Inc., USA) with a slight modification (Miller et al., 
1993). 
Statistical analyses were done using SPSS for windows 
(version 12.0, SPSS Inc, Chicago). Means and standard deviation 
of measures were calculated for all subjects, male and female, 
and subjects with and without individual metabolic risk factors 
and metabolic syndrome. Based on metabolic risk factors which 
defines metabolic syndrome presented by the National Choles-
terol Education Program Adult Treatment Panel III (NCEP ATP 
III, 2001), metabolic risk factors were defined as TG (≥
150 mg/dl), HDL (male <40 mg/dl, female <50 mg/dl), blood 
pressure (≥130/85 mmHg), impaired fasting glucose and obesity. 
The level of impaired fasting glucose was defined as fasting 
glucose ≥100 mg/dl, as presented by the Expert Committee on 
the Diagnosis and Classification of Diabetes Mellitus (2003). 
Obesity was defined by waist circumference (male ≥90 cm, 
female ≥85 cm) based on the definition newly presented by the 
Korean Society for the Study of Obesity (Lee et al., 2007) and 
BMI (≥25) based on Asia-Pacific definition presented by World 
Health Organization (WHO) West Pacific Region (2000). 
Subjects were divided into two groups with and without 
metabolic risk factor such as obesity, dyslipidemia, increased 
blood pressure and fasting glucose. Of tested metabolic risk 
factors, TG, HDL, blood pressure, fasting glucose and central 
obesity, subjects who had 3 and more metabolic risk factors were 
considered to be the group with metabolic syndrome. Differences 
of mean TAS between the groups were assessed by independent 
two-tailed t-tests. Pearson's correlation coefficients were used to 
assess the relationship between two variables of TAS and 
metabolic risk factors. The correlation between the number of 
metabolic syndrome components and TAS level was assessed 
by Spearman's correlation coefficient by rank. In all analyses, 
p<0.05 was considered statistically significant. 
Results
Anthropometric and biochemical measures of subjects are 
shown in Table 1. Four hundreds six subjects were consisted 
of 74 males and 332 females. Mean ages of subjects were 47.9
± 10.6 years for all subjects, 46.7 ± 10.8 years for males, and 
48.2 ± 10.5 years for females. Age ranges of male and female 
subjects were from 27 to 68, and from 20 to 78 years, 
respectively. The proportions of each age group for male subjects 
were 3, 26, 36, 19, and 16% for 20s, 30s, 40s, 50s and 60s, 
respectively. For female subjects, each proportion of 20s, 30s, Ho-Kyung Kwak and Sun Yoon 337
Table 2. Pearson’s correlation coefficients between measures
  Age Weight BMI
1) WC
2) SP
3) DP
4) TC
5) TG
6) LDL
7) HDL
8) Glucose
Weight 0.091*           
BMI 0.281** 0.856**          
WC 0.288** 0.755** 0.747**         
SP 0.325** 0.431** 0.446** 0.402**        
DP 0.267** 0.448** 0.461** 0.385** 0.877**       
TC 0.263** 0.115** 0.165** 0.174** 0.129** 0.106**      
TG 0.177** 0.362** 0.326** 0.347** 0.273** 0.268** 0.303**     
LDL 0.233** 0.100* 0.159** 0.135** 0.062 0.048 0.873** -0.037    
HDL -0.079 -0.388** -0.347** -0.315** -0.174** -0.196** 0.203** -0.436** 0.043   
Glucose 0.151** 0.186** 0.236** 0.222** 0.094* 0.089* -0.030 0.257** -0.106** -0.178**  
TAS 0.038 0.144** 0.106* 0.119* 0.067 0.066 0.103* 0.222** 0.005 -0.041 0.080
 *  C o r r e la t i o n  is  s i g n i f ic a n t  a t  t h e  0 . 0 5  level 
* *  C o r r e l a t i o n  i s  s i g n i f i c a n t  a t  t h e  0 . 0 1  level 
1) BMI: Body mass index, 
2) WC: Waist circumference, 
3) SP: Systolic blood pressure, 
4) DP:  Diastolic  blood  pressure, 
5) TC: Total cholesterol, 
6) TG: Triglyceride, 
7) LDL: Low 
density  lipoprotein, 
8) HDL:  High  density  lipoprotein 
Table 3. Comparison of TAS between groups with and without metabolic risk 
factors
 Mean SD n p
*
TG
1)     
    ≥ 150 mg/dl 1.08 0.33 91
0.001
    ＜ 150 mg/dl 0.94 0.34 315
HDL
2)     
    ＜ 40 mg/dl
a ＜ 50 mg/dl
b 0.95 0.25 70
0.495
    ≥ 40 mg/dl
a ≥ 50 mg/dl
b 0.98 0.35 336
Blood pressure
3)     
    ≥ 130 / 85 mmHg 1.01 0.36 76
0.249
    ＜ 130 / 85 mmHg 0.96 0.34 328
Fasting glucose
4)     
    ≥ 100 mg/dl 1.01 0.34 70
0.345
    ＜ 100 mg/dl 0.97 0.34 336
Waist circumference
5)     
    ≥ 90 cm
a ≥ 85 cm
b 1.03 0.33 93
0.054
    ＜ 90 cm
a ＜ 85 cm
b 0.96 0.36 310
BMI
6)     
    ≥ 25 1.03 0.36 71
0.096
    ＜ 25 0.96 0.32 334
Metabolic syndrome
7)     
    Yes 1.05 0.36 52
0.080
    No 0.96 0.34 354
1),2),3) National  Cholesterol  Education  Program  Adult  Treatment  Panel  III  (2001) 
4) Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (2003) 
5) K o r e a n  S o c ie t y  f o r  t h e  S t u d y  o f  O b e s it y  ( 2 0 0 7 ) 
6) Asia-Pacific definition presented by World Health Organization West Pacific Region 
(2000) 
7) Subjects who had 3 and more metabolic risk factors (Waist circumference, TG, 
H D L ,  b l o o d  p r e s s u r e  a n d  f a s t i n g  g l u c o s e )  
a Male, 
b Female 
* Significance  by  independent  samples  t-test 
Fig. 1. Distribution of the serum TAS according to the number of metabolic 
risk factors
The correlation between the number of metabolic syndrome components and TAS 
level  by  Spearman's  rank  correlation  coefficient.
40s, 50s, 60s and 70s was 3, 20, 31, 31, 11 and 4%, respectively. 
Among all subjects, there were 229 subjects aged <50 years and 
177 subjects aged ≥50 years. Of all measures, the mean height, 
weight, BMI, waist circumference, WHR, blood pressure and 
level of TG were significantly higher in males than females 
(p<0.001). In addition, serum TAS was shown to be higher in 
males than females (p=0.001). However, there was no significant 
difference in mean levels of TC, LDL and fasting glucose 
between gender groups, and the mean level of HDL was signi-
ficantly higher in the female group (p<0.001). 
Table 2 shows the Pearson's correlation coefficient between 
TAS and tested metabolic risk factors. TAS was significantly 
positively correlated with weight (p=0.004), BMI (p=0.033), 
waist circumference (p=0.017), TC (p=0.038) and TG (p<0.001). 
Table 3 shows the comparison of TAS between groups with and 
without metabolic risk factors, such as hypertriglyceridemia (≥
150 mg/dl), low HDL concentration (male <40 mg/dl, female 
<50 mg/dl), high blood pressure (≥130/85 mmHg), hypergly-
cemia (fasting glucose ≥100 mg/dl), central obesity (waist 
circumference, male ≥90 cm, female ≥85 cm) and BMI (≥25). 
Among the 406 subjects, 91 (male 39, female 52) subjects had 
serum TG level ≥150 mg/dl, and their mean TAS was signi-
ficantly higher (p=0.001) than mean TAS of subjects whose 
serum TG levels were <150 mg/dl. In addition, the mean TAS 
of 93 (male 30, female 63) central obese subjects and of 71 (male 
28, female 43) obese subjects (BMI ≥25) were shown to be 
7-8% higher than relative mean TAS of non-obese subjects, but 
this difference did not reach the significance (p=0.054, 0.096). 
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concentrations (15 males and 55 females) showed no notable 
difference as compared to the group with normal HDL con-
centrations. A total of 76 (male 26, female 50) and 70 (male 
20, female 50) subjects were found to have high blood pressure 
(≥130/85 mmHg) and fasting hyperglycemia (fasting glucose ≥
100 mg/dl), respectively. When groups with and without these 
metabolic risk factors, the groups with high blood pressure or 
hyperglycemia showed a small tendency to have higher (4-5%) 
mean TAS than groups without these metabolic risk factors. 
Table 3 also shows a comparison of mean TAS between 
subjects with and without metabolic syndrome. Twenty two 
males and 30 females had 3 and more metabolic risk factors 
among increased TG, fasting glucose, blood pressure, low HDL 
and central obesity. Mean TAS of 52 subjects with metabolic 
syndrome was 9% higher than that of subjects without metabolic 
syndrome, but the difference did not reach its significance 
(p=0.08). When subjects were divided into two groups (older 
≥50 y, younger <50 y), 34 out of 177 older subjects and 18 
out of 229 younger subjects had metabolic syndrome. In each 
older and younger age group, the mean TAS of subjects with 
metabolic syndrome showed 8 and 10% higher than that of 
subjects without metabolic syndrome, respectively. However, 
these differences did not reach their significance (p>0.1). Of all 
subjects, 183 did not have any of the 5 metabolic risk factors, 
and their mean TAS (0.94 ± 0.36) tended to be lower than the 
52 subjects with ≥3 metabolic risk factors (p=0.052). Fig. 1 
illustrates the distribution of TAS according to the number of 
metabolic syndrome components, and the median TAS was 
elevated with increasing metabolic risk factors (p=0.004). 
Discussion
TAC measured by commercially available TAS tended to be 
increased with various metabolic risk factors, especially obesity 
and increased serum lipids. TAS was significantly positively 
related with increased weight, BMI and waist circumference, and 
tended to be higher in obese subjects. Obesity has shown to 
increase oxidative stress by increased LDL oxidation and 
malondialdehyde (MDA), and these markers of oxidative stress 
have found to be related with BMI and WHR (Mohn et al., 2007). 
However, TAC measured with various methods has not seemed 
to decrease in overweight and obese people (Bae, 2006; Kim 
et al., 2000; Molnar et al., 2004; Sharifian et al., 2005). Similar 
to the findings from the present study, TAS was significantly 
higher in overweight adult males (Kim et al., 2000) and tended 
to be, but not significantly, higher in obese children (Molnar 
et al., 2004), as compared to controls. In addition, TAS was found 
to be significantly positively correlated with weight and BMI 
in 158 adults with and without hypertension (Kim et al., 2006). 
These findings including the results from the present study 
consistently suggest that weight gain may increase serum or 
plasma TAS level. 
In previous studies, obesity has often been accompanied with 
increased serum TG and TC (Ahn et al., 2005; Kim & Oh, 2007). 
The present study also showed a significantly positive association 
of serum TG and TC with weight, BMI and waist circumference. 
In conjunction with obesity, serum TG and TC significantly 
positively correlated with TAS, and subjects with high serum 
TG (≥150 mg/dl) showed that their mean TAS was significantly 
higher than subjects whose serum TG were lower than 150 mg/dl. 
However, the findings in the association between TAS and 
increased TG and/or TC in various metabolic conditions have 
shown to vary. When sedentary ex-athletes were compared with 
physically active ex-athletes, there was no difference in TAS, 
while TG and TC were significantly higher in sedentary 
ex-athletes (Pihl et al., 2003). In a study with psoriasis patients, 
there was a lower TAS observed along with higher TG and TC 
than controls (Kural et al., 2003). When dyslipidemia patients 
were treated with lipid lowering drug, TAS was increased as 
TG and TC were decreased (Kural et al., 2004). However, in 
a study by Belo et al. (2004), TG and TC were significantly 
increased with increased gestation period, as well as TAS and 
uric acid. Uric acid was also significantly correlated with TAS 
in each gestation periods (1st, 2nd and 3rd trimester). This 
significantly positive relationship between TAS and uric acid has 
been well recognized in previous studies (Kim et al., 2000; Kim 
et al., 2006).
In the present study, since we did not make an attempt to 
measure serum antioxidant parameters including uric acid, it 
limited us to evaluating magnitude of antioxidant contributions 
to TAS. However, we might be able to assume that uric acid 
did contribute serum TAS level, when we consider the report 
that 19.3% of Randox-TEAC called as TAS was contributed by 
uric acid (Cao & Prior, 1998). Uric acid was shown to be the 
second highest contributor among the known serum antioxidants, 
albumin (28.0%), ascorbic acid (3.08%), α-tocopherol (1.74%) 
and bilirubin (1.0%). In addition, uric acid was found to be 
elevated with overweight, obesity and visceral fat area (Hikita 
et al., 2007; Kim et al., 2000; Molnar et al., 2004). These 
previous findings may suggest the partial effect of increased uric 
acid on TAS in overweight and obese conditions, and explain 
in part the positive association among obesity indices and TAS 
shown in the current study. In addition, we also observed elevated 
TAS with increased TG and metabolic risk factors. Hikita et al., 
(2007) demonstrated that uric acid was elevated with increased 
number of metabolic risk factors, as well as TG, one of the most 
influential parameters on serum uric acid elevation. With respect 
to the relation between serum uric acid and metabolic risk factors, 
there was proportional elevation of uric acid levels when number 
of metabolic risk factors increased as 0, 1, 2 and ≥3 (Desai 
et al., 2005). In the present study, we observed similar tendency 
in elevated TAS with increased number of metabolic risk factors. 
Based on these observations, we might take it for granted that 
changes in serum uric acid affect TAS levels. Besides uric acid, 
serum albumin was also found to contribute TAS level by 28% Ho-Kyung Kwak and Sun Yoon 339
(Cao & Prior, 1998), and significantly correlated with TAS of 
17 normal weight young males (Kim et al., 2000). Further, there 
are still unknown serum antioxidants which hold the greatest 
proportion of contribution to TAS by 47% (Cao & Prior, 1998). 
Other than TAS, various biomarkers of oxidative stress have been 
employed in studies on antioxidant status in humans. Of those 
markers, plasma MDA and LDL oxidation are well-recognized 
biomarkers of oxidative stress which have shown to reflect 
changes in oxidative stress caused by increased body weight 
(Mohn  et al., 2005), aging (Mendoza-Nunez et al., 2007), 
exercise (Kim et al., 2001) and antioxidant supplementation 
(Giannini  et al., 2007). Unlike these biomarkers of oxidative 
stress, TAS did not consistently reflect the conditions with 
increased oxidative stress (Bae, 2006; Belo et al., 2004; Kim 
et al., 2000; Kim et al., 2001; Magalhaes et al., 2007; Mendoza- 
Nunez  et al., 2007). Further, with increased gestation period, 
changes in TAS were shown to be negatively correlated with 
changes in oxidized LDL, while increased oxidized LDL was 
accompanied with increased TG and LDL (Beloe et al., 2004). 
In the current study, TAC measure by TAS was significantly 
positively associated with obesity, as well as number of metabolic 
risk factors, although these conditions have known to be high 
in oxidative stress. Therefore, it seems that TAS appears to be 
affected by changes in individual antioxidant parameters which 
might be altered by various metabolic conditions. These 
antioxidant parameters affecting TAS values could be increased 
not only by body's increased antioxidant status, but by body's 
compensatory mechanism to counteract increased oxidative stress 
(Ames  et al., 1985). Since there are no individual antioxidant 
data available in the present study, we may not be able to strongly 
assume the factors directly affecting TAS in subjects with and 
without metabolic risk factors. However, it is worthy to note 
that positive associations between TAS and increased metabolic 
risk factors, especially obesity related parameters, were consis-
tently found in the present study and a few previous studies. 
This implies that increased TAS level may not always represent 
one’s healthier condition or condition with a low oxidative stress, 
suggesting that TAS may not be used as a sole indicator of 
oxidative stress marker. Further, it is necessary to clarify the 
unknown factors affecting TAS with relation to various metabolic 
conditions in order to have better understanding what the TAS 
level implies in certain metabolic conditions. 
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